RxDoctor Payments Data

Jonathan Olivas, MD

Psychiatry · Moorhead, MNNPI 1942599048

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Johnson & Johnson at 39.3% of the total. Reporting peaked in 2024 at $423 and has fallen 72.8% since, to $115 in 2025. Among psychiatry clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$831in general payments, 2019–2025

Across 15 payments — averaging $55.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$326
  • Axsome Therapeutics, Inc.$163
  • AbbVie$110
  • E.r. Squibb & Sons, L.L.C.$105
  • Sunovion Pharmaceuticals Inc.$78
  • Alkermes, Inc.$49

What the payments were for

  • Food & beverage$79295%
  • Education$395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$831 in reported general payments places this provider in the 90th percentile of 552 psychiatry providers in Minnesota.

See all psychiatry providers in Minnesota

Medicare billing

Part B allowed, 2024
$93,601
Medicare patients
146
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl30$45,899
Lurasidone Hcl16$12,032
Fluphenazine Hcl13$7,551
Divalproex Sodium ErDivalproex Sodium37$3,443
Bupropion XlBupropion Hcl72$2,471
Clozapine21$2,152
Duloxetine Hcl84$1,391
Mirtazapine56$1,333
Buspirone Hcl34$1,123
Methylphenidate Hcl40$1,079
Venlafaxine Hcl ErVenlafaxine Hcl37$898
Aripiprazole21$809
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$712
Fluoxetine Hcl46$511
Clonazepam80$489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$110$45,89930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 552 psychiatry providers in Minnesota.

Other psychiatry in Moorhead

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →